Could a gut bacteria boost cancer immunotherapy? new trial launches
NCT ID NCT07128680
First seen Jan 31, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This early-phase trial tests whether adding a live bacteria supplement (EXL01) to standard immunotherapy (nivolumab and ipilimumab) is safe and more effective for people with metastatic kidney cancer. About 33 participants will receive either the immunotherapy alone or with the supplement. The goal is to see if the bacteria can improve the immune response against the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV RENAL CELL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
City of Hope Medical Center
NOT_YET_RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, ipilimumab, and EXL01 (a live bacterial supplement)
What this could lead to
If it works, this could point toward a way to boost the immune system's attack on kidney cancer by adding a gut bacteria supplement to standard immunotherapy.
What could go wrong
This is a very early (Phase 1) and small (33 people) trial, so it is mainly checking safety. The bacteria supplement may not help, and side effects from the immunotherapy can be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.